Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Successful Lab Test of Photoswitchable Anti-Tumor Agent

By Drug Discovery Trends Editor | April 25, 2016

The GS-DProSw molecule in its inactive form (blue) can be activated by visible light (red) and "switched off" again by UV light. Source: Figure: KIT​Photoswitchable agents might reduce side effects of a chemotherapy. So far, photodynamic therapies have been dependent on oxygen in the tissue. But hardly any oxygen exists in malignant, rapidly growing tumors. A group of researchers of KIT and the University of Kiev has now developed a photo-switchable molecule as a basis of an oxygen-independent method. Their successful laboratory tests on tumors are reported in the journal Angewandte Chemie.

Photodynamic therapy (PDT) in medicine usually uses a substance that reacts to light and converts the oxygen in the tissue into aggressive radicals. These reactive substances are toxic and damage the neighboring cells, such that e.g. tumors are decomposed. As a result of their quicker growth, however, many tumors have a high oxygen consumption. This reduces the concentration of oxygen available in the tissue, which may aggravate conventional PDT.

Researchers of KIT and the University of Kiev have now developed a new photo-switchable molecule for oxygen-independent PDT. The effect of the GS-DProSw molecule can be “switched off” by ultraviolet light prior to therapy. Only upon application is it “switched on” in the tumor tissue by visible light and damages the tumor tissue there. “The surrounding organs remain in the dark and are not affected by the active substance,” Anne S. Ulrich, Professor for Biochemistry and Director of the KIT Institute for Biological Interfaces, explains. “As a result, side effects are reduced significantly.”

For the first time, this new concept has now been tested on animal models. Once per day, the photoswitchable GS-DProSw molecule was administered. Then, the tumors were irradiated locally with visible light for a period of 20 minutes. After ten days of PDT treatment, the tumors were found to be far smaller than comparative groups not treated with light.

To initiate an oxygen-independent reaction in a PDT, the molecule applied has to be of cytotoxic nature. This means that it has to directly attack the tumor tissue irrespective of other reaction partners. A suitable molecule with cytotoxic properties against tumors is the biomolecule gramicidin S (GS), a natural antibiotic. To prevent it from damaging healthy tissue, the research team inserted a photo-switchable diaryl ethene segment into the ring structure. As a result, the GS-DProSw molecule can be switched between two states with the help of light: The agent can be administered in the inactive state and is activated at the desired location by specific irradiation with light. There, it attacks the surrounding tumor tissue and contrary to conventional PDT, it does not require any oxygen for this purpose.

“This first proof of functioning represents an important step in fundamental research for the development of anti-tumor agents,” Ulrich explains. “But we still have a far way to go: To reliably use this type of photoswitchable molecules for a photodynamic therapy of patients, numerous other studies have to be carried out in cooperation with our partners in Kiev.”

Source: Karlsruher Institut Fur Technologie (KIT)


Filed Under: Drug Discovery

 

Related Articles Read More >

Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE